EP Patent

EP2589383A1 — FKBP subtype-specific rapamycin analogue for use in treatment of diseases

Assigned to Max Planck Gesellschaft zur Foerderung der Wissenschaften eV · Expires 2013-05-08 · 13y expired

What this patent protects

The present invention is directed to a FKBP subtype-specific rapamycin analogue selective for a single FKBP, wherein the FKBP subtype-specific rapamycin analogue preferentially forms a complex with only a single FKBP and this complex binds and/or inhibits the mammalian target of …

USPTO Abstract

The present invention is directed to a FKBP subtype-specific rapamycin analogue selective for a single FKBP, wherein the FKBP subtype-specific rapamycin analogue preferentially forms a complex with only a single FKBP and this complex binds and/or inhibits the mammalian target of rapamycin for use in treatment of cancer, depression, neurodegeneration, transplant rejection or metabolic disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP2589383A1
Jurisdiction
EP
Classification
—
Expires
2013-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.